Quadrant purchase adds CME muscle

Share this article:
Quadrant HealthCom plans to beef up its med ed offering through four titles recently acquired from Jobson.

“The idea is to integrate them into Quadrant and try to give them the kind of support they need to realize their potential,” said Steve Stoneburn, president and CEO of Quadrant. “We're optimistic we can continue to grow that business.”

The acquisitions broaden Quadrant's audience to 500,000 readers across 13 titles, bolstering its primary care portfolio and giving it entrée into the neurology, psychiatry, pulmonary and NP/PA specialty categories. The four titles include Clinician Reviews, Neurology Reviews, Neuropsychiatry Reviews and Pulmonary Reviews.

A fifth title included in the deal, Women's Health in Primary Care, will cease publication, with elements to be added to Quadrant's The Female Patient. Editor-in-chief Maura Griffith will serve as chief of content development activities at Quadrant Medical Education.

Roland DeSilva of DeSilva + Phillips, which brokered the deal for Quadrant, called it “an excellent strategic fit for Quadrant.”

Stoneburn said great synergies exist between the titles. “We've begun to develop a series of market-specific publications under the banner of Women's Health In…that utilizes the women's health content and branding but focus on more narrowly defined subjects,” he said.

Terms of the deal were not disclosed.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...